Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Unknown 2Terminated 2Active not recruiting 2Withdrawn 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 16Lymphoma 7Neoplasms, Plasma Cell 5Lymphoma, Large B-Cell, Diffuse 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Melanoma 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Burkitt Lymphoma 2Skin Neoplasms 1Sezary Syndrome 1Sarcoma, Ewing 1Sarcoma 1Rhabdoid Tumor 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroectodermal Tumors, Primitive 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Vorinostat 2Stem Cell Transplantation 2Rituximab 2Gemcitabine 2Busulfan 2Brentuximab Vedotin 2romidepsin 1pembrolizumab 1molibresib 1entinostat 1copanlisib 1belinostat 1Tacrolimus 1Pyridoxine 1Panobinostat 1Mycophenolic Acid 1Melphalan 1Health Resources 1Granulocyte Colony-Stimulating Factor 1Glutamine 1Filgrastim 1Fibroblast Growth Factor 7 1Dexamethasone 1Cyclophosphamide 1Cryotherapy 1Clofarabine 1Calcium Dobesilate 1CT-P10 1Bortezomib 1BI 6727 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, T-Cell × Melphalan × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡